Volume 5 Issue 8 (August, 2017)

Original Articles

Blood Pressure Response to Azilsartan in Hypertensive Patients
Praveen Kumar Chaudhary, V.K Bhalla

Background: Azilsartan is a novel angiotensin receptor blocker (ARB) being created for hypertension treatment. The primary point of this article is to assess the viability, wellbeing, and clinical part of azilsartan in hypertension patients. Materials and Methods: Total 70 hypertensive adults were incorporated into this examination. Parameters examined were age, indications, signs, examinations assuming any. All hypertensive grown-ups treated with Azilsartan 40 mg; alongside blood pressure response from day1, day 8 and day 30 were noted. The essential endpoint was change in trough facility diastolic blood pressure (DBP) at week 8. Result: Male to Female proportion of 41 : 29 and the age extending from 30 years to 65 years with mean age of 46.12 years. The commonest side effect was headache in took after by giddiness and weakness. Day 1 mean Systolic Blood weight was 162.31 mm Hg and mean Diastolic Blood weight was 94.54 mm Hg, after treatment with Azilsartan the mean Systolic Blood Pressure on day 8 was 140.22 mm Hg and mean Diastolic Blood preesure was 86.20 mm Hg, and day 30 mean systolic Blood weight was 130.45 mm Hg and mean Diastolic Blood weight was 83.73 mm Hg. Conclusion: Azilsartan medoxomil is a sheltered and powerful with a remarkable pharmacologic profile contrasted and different operators, including impeded angiotensin-II sort 1 (AT1) receptor separation rates and enhanced receptor specificity.
Keywords: Azilsartan medoxomil, angiotensin receptor blocker, hypertension, blood pressure.

Corresponding author: Dr. V.K Bhalla, Department of General Medicine, Rajshree Medical Research Institute, Bareilly, U.P, India

This article may be cited as: Chaudhary PK, Bhalla VK. Blood Pressure Response to Azilsartan in Hypertensive Patients. J Adv Med Dent Scie Res 2017;5(8):20-23.

Abstract View | Download PDF | Current Issue

This work is licensed under a Creative Commons Attribution 3.0 License.